Precision Ocular Biobank, United States

Certification Status: Approved

Registration Status: Completed

Objective: Advancing Sight Network (ASN) https://advancingsight.org/ is a certified 501c3 nonprofit organization and an accredited member of the Eye Bank Association of America (EBAA) and its headquarters are registered with the Food and Drug Administration (FDA) as a human tissue facility under FEI # 3001236642. Its affiliates operating in Mississippi, Tennessee and Louisiana are also accredited with the EBAA and registered with the FDA as human tissue facilities: Mississippi Lions Eye Bank FEI # 3000215041; MidSouth Eye Bank for Sight Restoration FEI # 1000524671; Southern Eye Bank FEI # 3000215034. The Precision Ocular Biobank (POB) is a division of ASN specializing in biobanking and distributing ocular tissue for research. The POB is registered with the International Society of Biological and Environmental Repositories (ISBER) and is certified through the Canadian Tissue Repository Network (CTRNet). The POB program (Protocol #20- POB-101) has been reviewed and approved (9/04/2020) by an independent Institutional Review Board, Pearl IRB (organization number: 0006471, registration number: 00007772). The POB is a registered supplier on Scientist.com. All donation procedures and processes practiced by ASN are consistent with the legal requirements of and protections afforded under the Alabama Revised Uniform Anatomical Gift Act of 2016 (UAGA); AL Code 22-19-160 â€“ 22-19-184, the Mississippi Revised UAGA of 2016; MS Codes 41-39-101 - 41-39-149, the Tennessee Revised UAGA of 2010; TN Codes 68-30-101 â€“ 68-30-403, and the Louisiana revised UAGA of 2010; LS Revised Statutes RS 17:2351 â€“ 17:2359. Only de-identified biological samples and data from fully authorized deceased donors are shared with approved researchers, thereby not constituting research involving human subjects.

Registered Biobank Name	Precision Ocular Biobank
Biobank Leader	Gregory Grossman
Country	United States
Email for biobank inquiries	ggrossman@advancingsight.org
Principal Investigator	Gregory Grossman
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).